IMUNON Submits Plan in Consultation with the Exchange to Ensure Compliance with Nasdaq’s Listing Requirement, Anticipates Additional Compliance Period
IMUNON (NASDAQ: IMNN), a clinical-stage biotechnology company, has submitted a compliance plan to Nasdaq to address listing requirements concerns. The company is working to meet minimum bid price and stockholders' equity requirements for continued listing on The Nasdaq Capital Market.
The company has requested a hearing before The Nasdaq Hearings Panel and expects to receive an additional 180-day compliance period. Trading of IMNN stock will continue during the hearing process. As of May 31, 2025, IMUNON's stockholders' equity exceeds $3.0 million, meeting Nasdaq's listing threshold.
IMUNON is currently advancing its lead program, IMNN-001, a DNA-based immunotherapy for advanced ovarian cancer treatment, which is in Phase 3 development. The company has initiated the Phase 3 (OVATION 3) trial in the U.S. and Canada following successful Phase 2 (OVATION 2) trial results.
IMUNON (NASDAQ: IMNN), un'azienda biotecnologica in fase clinica, ha presentato a Nasdaq un piano di conformità per affrontare le preoccupazioni relative ai requisiti di quotazione. La società sta lavorando per soddisfare i requisiti minimi di prezzo di offerta e patrimonio netto degli azionisti per mantenere la quotazione sul Nasdaq Capital Market.
La società ha richiesto un'udienza presso il Nasdaq Hearings Panel e prevede di ottenere un ulteriore periodo di conformità di 180 giorni. Il trading delle azioni IMNN continuerà durante il processo di udienza. Al 31 maggio 2025, il patrimonio netto degli azionisti di IMUNON supera i 3,0 milioni di dollari, soddisfacendo la soglia di quotazione di Nasdaq.
IMUNON sta attualmente portando avanti il suo programma principale, IMNN-001, un'immunoterapia a base di DNA per il trattamento del cancro ovarico avanzato, che si trova in fase 3 di sviluppo. La società ha avviato lo studio di Fase 3 (OVATION 3) negli Stati Uniti e in Canada, a seguito dei risultati positivi dello studio di Fase 2 (OVATION 2).
IMUNON (NASDAQ: IMNN), una empresa biotecnológica en etapa clínica, ha presentado un plan de cumplimiento a Nasdaq para abordar las preocupaciones sobre los requisitos de cotización. La compañía está trabajando para cumplir con los requisitos mínimos de precio de oferta y patrimonio de los accionistas para mantener su cotización en The Nasdaq Capital Market.
La empresa ha solicitado una audiencia ante el Nasdaq Hearings Panel y espera recibir un período adicional de cumplimiento de 180 días. La negociación de las acciones de IMNN continuará durante el proceso de audiencia. Al 31 de mayo de 2025, el patrimonio de los accionistas de IMUNON supera los 3.0 millones de dólares, cumpliendo con el umbral de cotización de Nasdaq.
Actualmente, IMUNON está avanzando con su programa principal, IMNN-001, una inmunoterapia basada en ADN para el tratamiento del cáncer de ovario avanzado, que se encuentra en fase 3 de desarrollo. La compañía ha iniciado el ensayo de Fase 3 (OVATION 3) en EE.UU. y Canadá tras los resultados exitosos del ensayo de Fase 2 (OVATION 2).
IMUNON (NASDAQ: IMNN)은 임상 단계의 생명공학 회사로서, 나스닥 상장 요건 관련 문제를 해결하기 위해 나스닥에 준수 계획을 제출했습니다. 회사는 나스닥 캐피탈 마켓에 계속 상장되기 위한 최소 입찰가 및 주주 자본 요건을 충족하기 위해 노력하고 있습니다.
회사는 나스닥 청문회 패널에 청문회를 요청했으며, 추가 180일 준수 기간을 받을 것으로 예상합니다. 청문회 과정 동안 IMNN 주식 거래는 계속됩니다. 2025년 5월 31일 기준으로 IMUNON의 주주 자본은 300만 달러를 초과하여 나스닥 상장 기준을 충족합니다.
IMUNON은 현재 주요 프로그램인 IMNN-001 DNA 기반 면역치료제를 진행 중이며, 이는 진행성 난소암 치료를 위한 3상 개발 단계에 있습니다. 회사는 2상(OVATION 2) 시험의 성공적인 결과에 이어 미국과 캐나다에서 3상(OVATION 3) 시험을 시작했습니다.
IMUNON (NASDAQ : IMNN), une société de biotechnologie en phase clinique, a soumis un plan de conformité à Nasdaq pour répondre aux préoccupations liées aux exigences de cotation. La société travaille à satisfaire les exigences minimales de prix d'offre et de capitaux propres des actionnaires pour maintenir sa cotation sur le Nasdaq Capital Market.
La société a demandé une audience devant le Nasdaq Hearings Panel et s'attend à recevoir une période de conformité supplémentaire de 180 jours. Le trading des actions IMNN se poursuivra pendant la procédure d'audience. Au 31 mai 2025, les capitaux propres d'IMUNON dépassent 3,0 millions de dollars, répondant ainsi au seuil de cotation de Nasdaq.
IMUNON fait actuellement progresser son programme principal, IMNN-001, une immunothérapie à base d'ADN pour le traitement du cancer de l'ovaire avancé, qui est en phase 3 de développement. La société a lancé l'essai de phase 3 (OVATION 3) aux États-Unis et au Canada suite aux résultats positifs de l'essai de phase 2 (OVATION 2).
IMUNON (NASDAQ: IMNN), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, hat einen Compliance-Plan bei der Nasdaq eingereicht, um Bedenken hinsichtlich der Börsennotierungsanforderungen auszuräumen. Das Unternehmen arbeitet daran, die Mindestgebotspreis- und Eigenkapitalanforderungen für die fortgesetzte Notierung am Nasdaq Capital Market zu erfüllen.
Das Unternehmen hat eine Anhörung vor dem Nasdaq Hearings Panel beantragt und erwartet eine zusätzliche 180-tägige Compliance-Frist. Der Handel mit IMNN-Aktien wird während des Anhörungsprozesses fortgesetzt. Zum 31. Mai 2025 übersteigt das Eigenkapital von IMUNON 3,0 Millionen US-Dollar und erfüllt somit die Nasdaq-Listenanforderungen.
IMUNON treibt derzeit sein führendes Programm, IMNN-001, eine DNA-basierte Immuntherapie zur Behandlung von fortgeschrittenem Eierstockkrebs, voran, das sich in der Phase-3-Entwicklung befindet. Das Unternehmen hat die Phase-3-Studie (OVATION 3) in den USA und Kanada nach erfolgreichen Ergebnissen der Phase-2-Studie (OVATION 2) gestartet.
- Stockholders' equity exceeds $3.0 million, meeting Nasdaq listing threshold
- Successfully initiated Phase 3 trial for IMNN-001 in U.S. and Canada
- Trading suspension stayed pending hearing process
- Potential 180-day extension period to regain compliance
- Company fails to meet Nasdaq minimum bid price requirement
- Non-compliance with minimum stockholders' equity requirement
- Faces potential delisting risk without compliance
Insights
IMUNON has submitted a plan to regain Nasdaq compliance, averting immediate delisting while advancing its Phase 3 cancer treatment program.
IMUNON is working to address two critical Nasdaq compliance issues: minimum bid price and stockholders' equity requirements. The company has already requested a hearing before the Nasdaq Panel, which has temporarily stayed the suspension of trading and potential delisting of their stock while the hearing process unfolds.
The most significant positive development is that IMUNON has already restored its stockholders' equity to
What's important for investors to understand is that IMUNON appears to be on a constructive path with Nasdaq. The company has established what they describe as a "pathway" to an additional 180-day compliance period, though this extension remains subject to the Panel's final review. This timeframe would provide substantial breathing room for the company to fully address compliance issues.
While navigating these regulatory challenges, IMUNON continues advancing its lead clinical program, IMNN-001, a DNA-based immunotherapy for advanced ovarian cancer that has progressed to Phase 3 trials in the U.S. and Canada following what the company characterizes as "unprecedented Phase 2 results." This parallel progress on both compliance and clinical development suggests management is executing on multiple fronts despite the listing challenges.
LAWRENCEVILLE, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that, in consultation with The Nasdaq Stock Market LLC (Nasdaq), it has submitted its plan to Nasdaq to regain compliance with the minimum bid price requirement and the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. On May 29, 2025, the Company requested a hearing before The Nasdaq Hearings Panel (“Panel”). At this hearing, the Company will request an extension to meet the requirements and return to compliance. In an exchange with Nasdaq, the Company has established a pathway to an additional compliance period of 180 calendar days to regain compliance with the minimum bid price requirement and the minimum stockholders’ equity requirement, subject to final review by the Panel. Pursuant to Nasdaq Listing Rule 5815(a)(1)(B), the hearing request stayed the suspension of trading and delisting of the common stock pending the conclusion of the hearing process.
“We are confident that our plan demonstrates our ability to regain compliance with Nasdaq's listing requirements, an important step that reflects our commitment to advancing our lead clinical program, IMNN-001, a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer which is now in a Phase 3,” said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. “We have made substantial progress following our unprecedented Phase 2 (OVATION 2) trial results, including initiating our Phase 3 (OVATION 3) trial in the U.S. and Canada, and look forward to achieving additional milestones in the development of our innovative TheraPlas® and PlaCCine® technology platforms.”
Following the completion of several recent financial transactions, the Company’s stockholders’ equity as of May 31, 2025, exceeds
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the Company’s ability to regain compliance with Nasdaq’s continued listing requirements, the timing of enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, risks and uncertainties related to our ability to regain compliance with Nasdaq’s listing requirements, the potential de-listing of our shares on Nasdaq, risks and uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Contacts:
| Media | Investors |
| Jenna Urban | Peter Vozzo |
| CG Life | ICR Healthcare |
| 212-253-8881 | 443-213-0505 |
| jurban@cglife.com | peter.vozzo@icrhealthcare.com |
FAQ
What is IMUNON's (IMNN) current Nasdaq compliance status?
What is the timeline for IMUNON (IMNN) to regain Nasdaq compliance?
What is IMUNON's (IMNN) current stockholders' equity position?
What is the current development stage of IMUNON's (IMNN) lead product?
Has IMUNON (IMNN) stock been suspended from trading?
